Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 3 art units • 7 examiners • 0 of 10 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Exact Sciences Corporation has 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 10 pending office actions are distributed among 7 distinct examiners. The portfolio involves 3 distinct art units. PRIEST, AARON A is the busiest examiner.
PRIEST, AARON A has 2 pending actions, which is the busiest examiner pending count. The 7 distinct examiners manage the 10 pending office actions, meaning some examiners handle more than one case. The 3 distinct art units suggest that the 10 pending office actions are grouped into three technical sub-categories.
The count of 10 pending office actions is higher than the count of 7 distinct examiners. This requires the company to coordinate across multiple individuals in the Biotechnology & Pharmaceuticals area. The 2 pending actions assigned to PRIEST, AARON A represent the highest concentration of work for any single examiner among the 7 distinct examiners.
Practitioners must manage the 10 pending office actions across 3 distinct art units, which may have different examination timelines. The 7 distinct examiners provide a variety of perspectives on the Biotechnology & Pharmaceuticals technology. The busiest examiner pending count of 2 indicates that the workload is not heavily dominated by a single person.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 2 (20%) |
| §112 only | 1 (10%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 1 (10%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, AARON A | 2 | 61.3% | +25.7% |
| SALMON, KATHERINE D | 2 | 42.8% | +37.9% |
| GOLDBERG, JEANINE ANNE | 2 | 45.8% | +40.8% |
| BROWN, MINDY G | 1 | 55.9% | +44.4% |
| XU, XIAOYUN | 1 | 60.0% | +31.8% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
| KENNEDY, SARAH JANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643723 | Method for Stabilizing Hemoglobin and Reagents for Performing the Same | XU, XIAOYUN | — |
| 17921711 | DETECTING MELANOMA | KENNEDY, SARAH JANE | — |
| 17741305 | METHYLATED CONTROL DNA | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17727128 | DETECTING ESOPHAGEAL DISORDERS | GOLDBERG, JEANINE ANNE | 104d overdue |
| 18943512 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | BROWN, MINDY G | 45d overdue |
| 18353647 | COMPOSITIONS AND METHODS FOR CHARACTERIZING ZDHHC1 DNA | HANEY, AMANDA MARIE | 33d |
| 18759437 | Multiplexed Kras Mutation Detection Assay | PRIEST, AARON A | — |
| 18732175 | MULTIPLEX AMPLIFICATION DETECTION ASSAY | PRIEST, AARON A | — |
| 18643723 | Method for Stabilizing Hemoglobin and Reagents for Performing the Same | XU, XIAOYUN | — |
| 18323031 | DETECTING PROSTATE CANCER | SALMON, KATHERINE D | — |
| 17741305 | METHYLATED CONTROL DNA | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 6 |
| 1683 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943512 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | BROWN, MINDY G | 1683 | §112 | Non-Final OA | 45d overdue | Pending | Nov 11, 2024 |
| 18759437 | Multiplexed Kras Mutation Detection Assay | PRIEST, AARON A | — | §103§112DP | Final Rejection | — | Pending | Jun 28, 2024 |
| 18732175 | MULTIPLEX AMPLIFICATION DETECTION ASSAY | PRIEST, AARON A | — | DP | Final Rejection | — | Pending | Jun 03, 2024 |
| 18643723 | Method for Stabilizing Hemoglobin and Reagents for Performing the Same | XU, XIAOYUN | 1797 | §102§103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18353647 | COMPOSITIONS AND METHODS FOR CHARACTERIZING ZDHHC1 DNA | HANEY, AMANDA MARIE | 1682 | Other | Non-Final OA | 33d | Pending | Jul 17, 2023 |
| 18323031 | DETECTING PROSTATE CANCER | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | — | Pending | May 24, 2023 |
| 17921711 | DETECTING MELANOMA | KENNEDY, SARAH JANE | 1682 | §101§103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17741305 | METHYLATED CONTROL DNA | GOLDBERG, JEANINE ANNE | 1682 | §101DP | Non-Final OA | — | Pending | May 10, 2022 |
| 17727128 | DETECTING ESOPHAGEAL DISORDERS | GOLDBERG, JEANINE ANNE | 1682 | §103DP | Non-Final OA | 104d overdue | Pending | Apr 22, 2022 |
| 17587963 | DETECTING THE PRESENCE OR ABSENCE OF MULTIPLE TYPES OF CANCER | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial